The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

Revita ® The Company has completed enrollment of a sufficient number of patients for the mid-point analysis of the REMAIN-1 pivotal study, which is evaluating Revita’s efficacy in maintaining weight ...

Oral GLP-1 RA peptide program clinical trial initiated Metsera has initiated ... In the study, MET-097i demonstrated significant and durable weight loss, including 7.5% reduction in body weight from ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists ... primarily because of ...

Stanley Wilfong, senior lecturer and program coordinator for nutrition sciences at Baylor said the drug reduces weight by ...